Binding molecules specific for CD73 and uses thereof

Patent metadata

Field	Value
Publication number	US-9938356-B2
Application number	US-201514936233-A
Country	US
Kind code	B2
Filing date	Nov 9, 2015
Priority date	Nov 10, 2014
Publication date	Apr 10, 2018
Grant date	Apr 10, 2018

Abstract

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

First claim

What is claimed is:

1. An isolated binding molecule or antigen-binding fragment thereof which specifically binds to CD73 comprising an antibody V L and an antibody V H , wherein the V L comprises the amino acid sequence comprising SEQ ID NO: 68; and wherein the V H comprises the amino acid sequence comprising SEQ ID NO: 82.

2. An isolated antibody or antigen-binding fragment thereof which specifically binds to CD73 comprising a V L and a V H comprising VL-CDR1, VL-CRD2, VL-CDR3, VH-CDR1, VH-CDR2, and VH-CDR3 wherein VL-CDR1 comprises SEQ ID NO: 46 VL-CDR2 comprises SEQ ID NO: 51, VL-CDR3 comprises SEQ ID NO: 56, VH-CDR1comprises SEQ ID NO: 36, VH-CDR2 comprises SEQ ID NO: 39,and VH-CDR3 comprises SEQ ID NO: 45.

3. The isolated antibody or antigen-binding fragment thereof according to any one of claims 1 , or 2 , which comprises a heavy chain constant region or fragment thereof.

4. The isolated antibody or antigen-binding fragment thereof according to any one of claims 1 or 2 , which is an antagonist of CD73.

5. The isolated antibody or antigen-binding fragment thereof according to claim 4 , wherein the CD73 is human CD73.

6. The pharmaceutical formulation comprising an effective amount of an anti-CD73 antibody, or antigen binding fragment thereof and an anti-PD-L1 antibody, or an antigen binding fragment thereof, wherein the anti-CD73 antibody is MEDI9447, Phen0203 hIgG1, or an antigen binding fragment thereof.

7. A pharmaceutical formulation of claim 6 , wherein the anti-PD-L1 is MEDI4736, BMS-936559, or MPDL3280A, or an antigen binding fragment thereof.

8. The pharmaceutical formulation comprising an effective amount of an anti-CD73 antibody, or an antigen binding fragment thereof and anti-CTLA4 antibody, or an antigen binding fragment thereof, wherein the anti-CD73 antibody is MEDI9447, Phen0203 hIgG1, or an antigen binding fragment thereof.

9. A pharmaceutical formulation of claim 8 , wherein the anti-CTLA4 antibody is ipilimumab or tremelimumab (ticilimumab, CP-675,206) or an antigen binding fragment thereof.

Assignees

• Medimmune Ltd

Inventors

• Hay Carl
• Sachsenmeier Kris
• Sult Erin
• Huang Qihui
• Pavlik Peter
• Damschroder Melissa
• Cheng Li
• Diedrich Gundo
• Rios-Doria Jonathan
• Hammond Scott
• Minter Ralph
• Rust Steve
• Guillard Sandrine
• Hollingsworth Robert
• Jermutus Lutz
• Durham Nicholas
• Leow Ching Ching
• Antonysamy Mary
• Geoghegan James
• Lu Xiaojun
• Rosenthal Kim

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K39/3955 Primary

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title